• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Forte Biosciences Inc. (Amendment)

    9/15/23 12:00:43 PM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FBRX alert in real time by email
    SC 13D/A 1 formsc13d.htm


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13D
    Under the Securities Exchange Act of 1934
    (Amendment No. ____4____)*
     
     
    Forte Biosciences, Inc.
    (Name of Issuer)
     
                                                                                                   Common Stock, $0.001 par value per share
    (Title of Class of Securities)
     
     34962G109
    (CUSIP Number)
     
     
    Braden Leonard,  BML Capital Management, LLC  65 E Cedar - Suite 2.  Zionsville,  IN  46077  Phone : 317-344-2447
    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)
     
     September 15, 2023
    (Date of Event which Requires Filing of this Statement)

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ☒.

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     

     

     
    1
    NAMES OF REPORTING PERSONS
     
     
     BML Investment Partners, L.P.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
     WC
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
     0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
     1735075
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
     
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
      1735075
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
      1735075
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
     4.78
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
     PN
     
     
     
     
     

    Item 1.  Security and Issuer.

    This Statement on Schedule 13D relates to the common stock, par value $0.001 per share (the “Common Stock”), of Forte Biosciences, Inc, Inc., a Delaware corporation (the “Issuer”).


    Item 2.  Identity and Background.

    a. Name
    BML Capital Management, LLC - The business address of BML Capital Management, LLC, is 65 E Cedar – Suite 2, Zionsville, IN 46077. The principal business of BML Capital Management, LLC, is to serve as the general partner to BML Investment Partners, L.P.

    Braden M. Leonard – Mr. Leonard’s business address is 65 E Cedar – Suite 2, Zionsville, IN 46077. Mr. Leonard’s principal business is to serve as managing member of BML Capital Management, LLC.


    b. Residence or Business Address


    See above, Item 2(a)

    c. Occupation


    See above, Item 2(a)

    d. Convictions
    During the past five years, none of BML Investment Partners, L.P., BML Capital Management, LLC or Braden M. Leonard have been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or a party to a civil proceeding of a judicial or administrative body of competent jurisdiction where as a result of such proceeding BML Investment Partners, L.P., BML Capital Management, LLC or Braden M. Leonard was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.



    e. Civil Judgments

    During the past five years, none of BML Investment Partners, L.P., BML Capital Management, LLC or Braden M. Leonard have been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or a party to a civil proceeding of a judicial or administrative body of competent jurisdiction where as a result of such proceeding BML Investment Partners, L.P., BML Capital Management, LLC or Braden M. Leonard was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.


    f. Citizenship


    Braden M. Leonard is a citizen of the United States of America.

    Item 3.  Source or Amount of Funds or Other Consideration.


    BML Investment Partners, L.P. holds 1,735,075 shares of Common Stock which were acquired using working capital

    Item 4.  Purpose of Transaction.

    State the purpose or purposes of the acquisition of securities of the issuer:

    BML Investment Partners, L.P. (the "Reporting Person") acquired the Common Stock beneficially owned by the Reporting Person in the ordinary course of purchasing, selling and investing in securities.

    BML plans to vote its shares in favor of proposals put forth by Camac Partners, LLC (“Camac”) and ATG Capital Management, LLC (“ATG”). 

    All of the shares of Common Stock reported herein as being beneficially owned by the Reporting Person were acquired for investment purposes. Except as set forth herein, the Reporting Person does not have any plans or proposals that relate to or would result in any of the transactions described in Item 4 of Schedule 13D.

    The Reporting Person reserves the right to acquire, or cause to be acquired, additional securities of the Issuer, to dispose of, or cause to be disposed, such securities at any time or to formulate other purposes, plans or proposals regarding the Issuer or any of its securities, to the extent deemed advisable in light of general investment and trading policies of the Reporting Person, market conditions or other factors.

    Describe any plans or proposals which relate to or would result in:

    a. An Acquisition or Disposition
    See above. 
    b. A Corporate Transaction:
    See above. 
    c. A Sale or Transfer of Assets:
    See above. 
    d. A Change in Board of Directors:
    See above. 
    e. A Change in Capitalization:
    See above. 
    f. Other Material Change:
    See above. 
    g. Changes to Charter
    See above. 
    h. Causing Delisting:
    See above. 
    i. Termination of Registration:
    See above. 
    j. A Similar Action:
     See above.


    Item 5.  Interest in Securities of the Issuer.


    a. State the aggregate number and percentage of the class of securities identified pursuant to Item 1 beneficially owned by each person named in Item 2. As of Sept 15, 2023, BML Investment Partners owns 1,735,071 shares of the issuer, which represents 4.78% of the shares outstanding.


    b. For each person named, indicate the number of shares as to which there is sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition, or shared power to dispose or to direct the disposition.

    The Fund has sole voting and dispositive power over the shares reported herein

    c. Describe any transactions that were effected during the past sixty days or since the most recent filing of Schedule 13D.

    Transaction Date
    Shares Purchased (Sold)
    Price per Share or Unit
         
         


    d. If any other person is known to have the right to receive or direct dividends or proceeds from the sale of securities, a statement to that effect should be included:None


    e. The date the reporting person ceased to be the beneficial owner of more than five percent of the class of securities: (If applicable)8/14/23
     
    Item 6.  Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

    Relationships with Respect to Securities of the Issuer

    Describe any contracts, arrangements, understandings or relationships among the persons named in Item 2 and between such persons and any person with respect to any securities of the issuer:
    N/A

    Item 7.  Material to Be Filed as Exhibits.
     
     N/A
     
     


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated:September 15, 2023
     
     
    COMPANY NAME
      BML Capital Management, LLC
     
    By:
     /s/ Braden M Leonard
       
    Name: Braden M Leonard 
       
    Title:Managing Member  
     
     

    Get the next $FBRX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $FBRX

    DatePrice TargetRatingAnalyst
    1/21/2025Buy
    TD Cowen
    4/8/2024$2.75Neutral → Buy
    Ladenburg Thalmann
    9/20/2021$4.00 → $3.50Sell → Buy
    Chardan Capital Markets
    9/20/2021$4.00 → $3.50Sell → Neutral
    Chardan Capital
    9/3/2021Buy → Hold
    Brookline Capital
    9/3/2021Buy → Neutral
    Ladenburg Thalmann
    9/3/2021$105.00 → $4.00Buy → Sell
    Chardan Capital Markets
    9/3/2021$4.00Buy → Hold
    Truist
    More analyst ratings

    $FBRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Forte Biosciences Announces Pricing of $75 Million Public Offering

      Forte Biosciences, Inc. (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the pricing of a public offering of 5,630,450 shares of its common stock at a price to the public of $12.00 per share and, in lieu of common stock to certain investors who so chose, pre-funded warrants to purchase up to 619,606 shares of common stock at a price to the public of $11.999 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.001 per share exercise price for each pre-funded warrant. In addition, Forte has granted the underwriters a 30-day option to purchase up to

      6/25/25 12:28:00 AM ET
      $FBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Forte Biosciences Announces Proposed Public Offering

      Forte Biosciences, Inc. (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of common stock. In addition, Forte expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock plus the shares of common stock underlying the pre-funded warrants sold in the offering. All of the shares of common stock and pre-funded warrants are being offered by Forte. The proposed offering is subject to

      6/24/25 4:01:00 PM ET
      $FBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Forte Biosciences Announces Positive Data in FB102 Celiac Disease Phase 1B Study

      Phase 2 Celiac Disease Trial Initiating with Topline Readout Expected in 2026 Forte will be Hosting a Conference Call to Discuss the Results at 8:30 am ET Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced positive data from a Phase 1b trial in celiac disease for lead program FB102 (FB102-101). The company will be hosting a conference call today at 8:30 am ET. Prof. Jason Tye-Din, Head of Celiac Research at the Walter and Eliza Hall Institute and principal investigator in the FB102-101 study will be participating in the call. Please connect to the call using the

      6/23/25 7:18:00 AM ET
      $FBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FBRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF FINANCIAL OFFICER Riley Antony A converted options into 375 shares and covered exercise/tax liability with 134 shares, increasing direct ownership by 0.77% to 31,599 units (SEC Form 4)

      4 - Forte Biosciences, Inc. (0001419041) (Issuer)

      7/3/25 4:22:07 PM ET
      $FBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Wagner Paul A. converted options into 1,250 shares and covered exercise/tax liability with 98 shares, increasing direct ownership by 1% to 80,940 units (SEC Form 4)

      4 - Forte Biosciences, Inc. (0001419041) (Issuer)

      7/3/25 4:20:51 PM ET
      $FBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF FINANCIAL OFFICER Riley Antony A converted options into 375 shares and covered exercise/tax liability with 154 shares, increasing direct ownership by 0.71% to 31,218 units (SEC Form 4)

      4 - Forte Biosciences, Inc. (0001419041) (Issuer)

      4/2/25 5:03:05 PM ET
      $FBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FBRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF FINANCIAL OFFICER Riley Antony A bought $124,998 worth of shares (22,514 units at $5.55), increasing direct ownership by 273% to 30,776 units (SEC Form 4)

      4 - Forte Biosciences, Inc. (0001419041) (Issuer)

      11/22/24 5:45:42 PM ET
      $FBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wagner Paul A. bought $7,525 worth of shares (10,000 units at $0.75), increasing direct ownership by 0.55% to 1,823,236 units (SEC Form 4)

      4 - Forte Biosciences, Inc. (0001419041) (Issuer)

      12/20/23 10:56:32 AM ET
      $FBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wagner Paul A. bought $14,551 worth of shares (20,520 units at $0.71), increasing direct ownership by 1% to 1,813,236 units (SEC Form 4)

      4 - Forte Biosciences, Inc. (0001419041) (Issuer)

      12/15/23 6:29:33 PM ET
      $FBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FBRX
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by Forte Biosciences Inc.

      SCHEDULE 13G - Forte Biosciences, Inc. (0001419041) (Subject)

      7/8/25 7:50:29 AM ET
      $FBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by Forte Biosciences Inc.

      424B5 - Forte Biosciences, Inc. (0001419041) (Filer)

      6/25/25 5:22:15 PM ET
      $FBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Forte Biosciences Inc.

      8-K - Forte Biosciences, Inc. (0001419041) (Filer)

      6/25/25 4:45:18 PM ET
      $FBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FBRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • TD Cowen initiated coverage on Forte Biosciences

      TD Cowen initiated coverage of Forte Biosciences with a rating of Buy

      1/21/25 7:45:55 AM ET
      $FBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Forte Biosciences upgraded by Ladenburg Thalmann with a new price target

      Ladenburg Thalmann upgraded Forte Biosciences from Neutral to Buy and set a new price target of $2.75

      4/8/24 7:21:57 AM ET
      $FBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Forte Biosciences upgraded by Chardan Capital Markets with a new price target

      Chardan Capital Markets upgraded Forte Biosciences from Sell to Buy and set a new price target of $3.50 from $4.00 previously

      9/20/21 7:50:23 AM ET
      $FBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FBRX
    Leadership Updates

    Live Leadership Updates

    See more
    • Jasper Therapeutics Appoints Scott Brun, M.D., to its Board of Directors

      Dr. Brun also appointed as Chairperson of Jasper Research and Development Committee and to Compensation Committee Board member Vishal Kapoor appointed to Jasper Audit and Compensation Committees REDWOOD CITY, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria (CSU), lower to intermediate risk myelodysplastic syndromes (LR-MDS) as well as novel stem cell transplant conditioning regimes, today announced the appointment of Scott Brun, M.D., to Jasper's Board of Directors. Dr. Bru

      6/20/23 8:00:00 AM ET
      $CABA
      $FBRX
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Forte Biosciences, Inc. Announces Third Quarter 2022 Results and Provides Business Update

       -FB-102 Continues to Advance Towards the Clinic and Holds Significant Market Potential Across a Variety of Indications- -Leadership Strengthened with the Appointment of Scott Brun, M.D. to the Board of Directors- -Ended third quarter 2022 with approximately $44.0 million in cash and cash equivalents- Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced third quarter 2022 results and provided a business update. "Forte is making excellent progress with its lead program FB-102, which is a direct result of the team's hard work and diligent efforts. FB-102 holds significant potential in a variety of indicatio

      11/14/22 4:01:00 PM ET
      $FBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dr. Scott Brun, M.D. Appointed to Forte Biosciences Board of Directors

      -Forte Leadership is Significantly Strengthened with the Appointment of Dr. Scott Brun, M.D. to the Board of Directors Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), announced today that Dr. Scott Brun, M.D. has been appointed to the Forte Biosciences Board of Directors. Dr. Brun is currently a Venture Partner at Abingworth and in addition to his consulting practice, he is also a Senior Advisor for Horizon Therapeutics, and a Senior Medical Advisor at Launch Therapeutics. Dr. Brun previously served in numerous executive capacities at AbbVie, most recently as Head of AbbVie Ventures. In Dr. Brun's previous role as Head of Product Development at Abbvie, he led the global organi

      11/14/22 4:01:00 PM ET
      $FBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FBRX
    Financials

    Live finance-specific insights

    See more
    • Forte Biosciences Announces Positive Data in FB102 Celiac Disease Phase 1B Study

      Phase 2 Celiac Disease Trial Initiating with Topline Readout Expected in 2026 Forte will be Hosting a Conference Call to Discuss the Results at 8:30 am ET Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced positive data from a Phase 1b trial in celiac disease for lead program FB102 (FB102-101). The company will be hosting a conference call today at 8:30 am ET. Prof. Jason Tye-Din, Head of Celiac Research at the Walter and Eliza Hall Institute and principal investigator in the FB102-101 study will be participating in the call. Please connect to the call using the

      6/23/25 7:18:00 AM ET
      $FBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clinical Trial of FB-401 For the Treatment of Atopic Dermatitis Fails to Meet Statistical Significance

      Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company, today announced that topline data from its Phase 2 clinical trial of FB-401 for the treatment of atopic dermatitis failed to meet statistical significance for the primary endpoint of EASI-50 (the proportion of patients with at least a 50% improvement in atopic dermatitis disease severity as measure by EASI). Positive trends were observed in key secondary endpoints including EASI-90 with 27.6% of subjects in the active arm achieving the EASI-90 endpoint compared to 20.5% in the control arm (p=0.3075) and in IGA success (2 point reduction and clear or almost clear) with 38.2% of active sub

      9/2/21 4:05:00 PM ET
      $FBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Forte Biosciences, Inc. to Review the Second Quarter 2021 Results and Expects to Announce Topline Data From Phase 2 Clinical Trial of FB-401 for the Treatment of Atopic Dermatitis on Sept. 7

      Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company, will review the second quarter results and, based on the projected timing of database lock and completion of statistical programming and analysis, expects to announce topline data from its Phase 2 clinical trial of FB-401 for the treatment of atopic dermatitis on September 7, 2021. Conference Call and Webcast Information Forte management will host a conference call and webcast on Tuesday, September 7th at 8.00 AM Eastern Time. Participants may access the call by dialing 877-705-6003 (Domestic) or 201-493-6725 (International). The conference ID number is: 13722132. Participants may also

      8/16/21 4:05:00 PM ET
      $FBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FBRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Forte Biosciences Inc.

      SC 13G/A - Forte Biosciences, Inc. (0001419041) (Subject)

      12/6/24 4:05:50 PM ET
      $FBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Forte Biosciences Inc.

      SC 13G/A - Forte Biosciences, Inc. (0001419041) (Subject)

      11/14/24 4:31:51 PM ET
      $FBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Forte Biosciences Inc.

      SC 13G/A - Forte Biosciences, Inc. (0001419041) (Subject)

      11/14/24 4:02:27 PM ET
      $FBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care